Patent: 7,655,221
✉ Email this page to a colleague
Summary for Patent: 7,655,221
Title: | Methods of treating disease with random copolymers |
Abstract: | The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein. |
Inventor(s): | Rasmussen; James (Cambridge, MA), Zhang; Jianxin (Acton, MA), Baldwin; Sam (Westford, MA), Zanelli; Eric (Sudbury, MA), Yu; Bei (West Roxbury, MA), Bonnin; Dustan (Belmont, MA), Johnson; Keith (Hudson, MA) |
Assignee: | Peptimmune, Inc. (Cambridge, MA) |
Application Number: | 11/283,406 |
Patent Claims: | see list of patent claims |
Details for Patent 7,655,221
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Pharmacia & Upjohn Company Llc | ATGAM | lymphocyte immune globulin, anti-thymocyte globulin (equine) | Injection | 103676 | 12/04/1996 | ⤷ Try a Trial | 2024-05-07 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2024-05-07 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2024-05-07 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2024-05-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |